 |
|
|
Considering aesthetic surgery? You need to do your research and become an informed consumer.
Home
Information about Anti-Aging Products and Their Active
Ingredients
WRINKLE RELAX
TRIA LASER HAIR REMOVAL SYSTEM
Hydroderm
Strivectin Eye Cream Celebrity Plastic
Surgery Celebrity Cosmetic Surgery Whose Had it??
Bion Ceramic Flat Iron
GoSMILE TOOTH WHITENING
FROWNIES
HOLLYWOOD'S BEST
KEPT SECRET
RICAUD
TRUE COSMETICS
BEING TRUE
|
 (press release from Reliant Technologies)
SAN DIEGO---July 13, 2004--The Reliant FRAXEL(TM) SR laser has now gained additional 510(k) clearances to treat pigmented lesions (including age spots, sun spots and skin discoloration) at any location on the body and periorbital (around the eye) wrinkles, joining the clearance obtained in 2003 for dermatological conditions requiring the coagulation of soft tissue. As of July 1, 2004, the Reliant FRAXEL(TM) SR laser has FDA 510(k) clearance for: -- Dermatological procedures requiring the coagulation of soft tissue. -- Photocoagulation of pigmented lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and dyschromia. -- Treatment of periorbital wrinkles. Reliant FRAXEL(TM) Laser Treatment is a breakthrough technology based on a new science of "fractional" skin repair. By treating a fraction of the skin's surface at a time, FRAXEL(TM) Laser Treatment provides the positive results of traditional skin resurfacing without the down time and risks. The first FRAXEL(TM) laser installations across the U.S. are scheduled for the fourth quarter of 2004, with widespread treatment available by January 2005. The FDA clearances are based upon the clinical study of 30 patients with skin types I-III. These patients showed improvement in periorbital wrinkles and linear shrinkage in tissue as early as one week post-treatment. Minimal swelling and redness were the only side effects reported, and these resolved within 1-2 days. Treatment was well tolerated with minimal pain scores, largely due to spared tissue that remains between microthermal treatment zones. "These three FDA clearances are based on two of six studies planned for completion in 2004," said Len DeBenedictis, Reliant President and Chief Technology Officer. "Patients, investigators and prominent, expert dermatologists agreed that there were compelling improvements in wrinkles, texture and discoloration after FRAXEL(TM) treatment, which is a powerful endorsement of the versatility and functionality of this new science and technology." Reliant Technologies is positioned for growth and poised to become a new market leader in aesthetic laser medicine, surgery and biomedical technologies. Reliant is dedicated to fulfilling the promise of laser medicine by creating breakthrough systems focused on FRAXEL(TM) Laser Treatment. Reliant employs 50 professionals in two primary locations, San Diego and Palo Alto, California. For more information, visit: www.reliant-tech.com NDTosk Communications If You Found this Article Helpful You May Enjoy these articles: Thermage(R) Receives FDA Clearance for Full Face Treatment Thermage(R) Big Fast Treatment Tip Makes A Big Difference in Tissue Tightening and Contouring Thermage Complications
and |
PROACTIV SOLUTION ACNE TREATMENT
|
|
Type in your search words below
|
All contents copyright ©2000-2011
- Cosmetic Surgery News - All rights reserved.